Frankfurt
06.12.24
08:01 Uhr
0,000 Euro
0,000
0,00 %
0,00 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Nasdaq Stockholm AB: Delisting of Cyxone AB from Nasdaq First North Growth Market | 72 | GlobeNewswire | On December 9, 2024, Cyxone AB was declared bankrupt by Malmö District Court.
According to item 8.2.7 of the Nasdaq First North Growth Market Rulebook, the exchange may decide to delist the financial... ► Artikel lesen | |
| 06.12. | XFRA 4CX: AUSSETZUNG/SUSPENSION | 104 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCYXONE AB SK-,75... ► Artikel lesen | |
| 12.11. | Nasdaq Stockholm AB: Cyxone AB receives observation status | 157 | GlobeNewswire | On November 8, 2024, Cyxone AB (the "Company") disclosed a press release with
information on the Company's financial situation.
The rules of Nasdaq First North Growth Market state that an issuer can... ► Artikel lesen | |
| 08.11. | Nasdaq Stockholm AB: Lift of Suspension in Cyxone AB at FNSE | 188 | GlobeNewswire | Lifting of Suspension
At Trading Venue FNSE
Issuer: Cyxone AB, LEI: 54930034OH16ROAY4K87
--------------------------------------------------------------------------------
Instruments:... ► Artikel lesen | |
| 26.08. | Cyxone AB announces last day of trading in BTA | 4 | Cision News | ||
| 16.08. | Cyxone AB publishes outcome of rights issue | 4 | Cision News | ||
| 01.08. | The subscription period in Cyxone's rights issue starts today | 15 | Cision News | ||
| CYXONE Aktie jetzt für 0€ handeln | |||||
| 31.07. | Cyxone AB publishes investment memorandum | 1 | Cision News | ||
| 26.07. | XFRA CAPITAL ADJUSTMENT INFORMATION - 26.07.2024 | 265 | Xetra Newsboard | Das Instrument 1NN ES0105251005 NEINOR HOMES SA EO 8,21 EQUITY wird cum Kapitalmassnahme gehandelt am 26.07.2024 und ex Kapitalmassnahme am 29.07.2024 The instrument 1NN ES0105251005 NEINOR HOMES SA... ► Artikel lesen | |
| 23.07. | CYXONE: The board decides on a rights issue of a maximum of approximately SEK 23 million to finance continued development of rabeximod and T20K | 4 | Cision News | ||
| 15.07. | Cyxone provides an update on its research and development program | 2 | Cision News |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 108,60 | +0,09 % | Abstieg und Hoffnung: So steht es um den BioNTech-Konkurrenten Moderna | Die Aktie von Moderna hat in den vergangenen zwölf Monaten eine enttäuschende Entwicklung hingelegt. Im Nasdaq 100 gehört sie in diesem Zeitraum zu den zwei schlechtesten Werten. Nun muss sie den Index... ► Artikel lesen | |
| VALNEVA | 1,971 | +0,51 % | Valneva: Kooperation für Chikungunya-Impfstoff in Asien | Valneva hat eine exklusive Lizenzvereinbarung mit dem Serum Institute of India (SII) getroffen, um seinen Chikungunya-Impfstoff in Asien verfügbar zu machen. Die Kooperation ermöglicht den Zugang zu... ► Artikel lesen | |
| NOVAVAX | 8,319 | -0,45 % | Peering Into Novavax's Recent Short Interest | ||
| BAVARIAN NORDIC | 25,630 | -0,27 % | Bavarian Nordic: Deal in Indien - die Hintergründe | Zum Start in die neue Handelswoche hat der Impfstoff-Hersteller Bavarian Nordic eine neue Zusammenarbeit bekanntgegeben. Das Unternehmen schließt einen Lizenz- und Herstellungsvertrag für seinen Mpox-Impfstoff... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,700 | +8,00 % | COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs | Continued execution on merger integration with Ceapro Inc. and advancements across business Company ended the quarter with US$20.0 million in cash TORONTO, ONTARIO, Nov. 12, 2024 (GLOBE... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,730 | -0,57 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | Marlborough, Massachusetts--(Newsfile Corp. - December 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA... ► Artikel lesen | |
| ORAGENICS | 0,366 | -1,37 % | ORAGENICS INC - S-1, General form for registration of securities | ||
| LEXICON PHARMACEUTICALS | 0,693 | +1,39 % | Lexicon Pharmaceuticals, Inc.: Lexicon Announces Receipt of Complete Response Letter for Zynquista (sotagliflozin) | THE WOODLANDS, Texas, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it has received a complete response letter (CRL) from the U.S. Food and Drug Administration... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,260 | -4,41 % | CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES FIRST PATIENT ENROLLED IN THE GLOBAL MULTICENTER PHASE IB CLINICAL TRIAL OF CS5001 ... | ||
| OUTLOOK THERAPEUTICS | 1,390 | +0,72 % | Outlook Therapeutics, Inc. - 8-K, Current Report | ||
| NANOSPHERE HEALTH SCIENCES | 0,020 | -50,00 % | Nanosphere Health Sciences Inc (2): Nanosphere Health Sciences to hold AGM Dec. 13 | ||
| GENSCRIPT BIOTECH | 1,180 | -1,67 % | GENSCRIPT BIO (01548): COMPANY EXERCISES THE CONVERSION RIGHTS OF THE CONVERTIBLE BOND ISSUED BY PROBIO CAYMAN | ||
| KRYSTAL BIOTECH | 157,25 | -0,44 % | Krystal Biotech, Inc.: Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer | Preliminary clinical data in post-anti-PD-1 NSCLC patients demonstrated a 27% ORR and 73% DCR in monotherapy trial Monotherapy activity with inhaled KB707 provides further evidence of successful... ► Artikel lesen | |
| VERVE THERAPEUTICS | 5,735 | +11,04 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29,... ► Artikel lesen | |
| LEAP THERAPEUTICS | 2,660 | -4,32 % | Leap Therapeutics, Inc.: Leap Therapeutics Reports Third Quarter 2024 Financial Results | CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology... ► Artikel lesen |
CYXONE AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYXONE AB finden Sie auf Wallstreet Online.
